Prise en charge du syndrome de Nelson: données actuelles

Nelson, 1958, ACTH producing tumor of the pituitary gland, N. Engl. J. Med., 259, 161, 10.1056/NEJM195807242590403 Assie, 2004, The Nelson’s syndrome revisited, Pituitary, 7, 209, 10.1007/s11102-005-1403-y Jenkins, 1995, The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome, J. Clin. Endocrinol. Metab., 80, 165, 10.1210/jc.80.1.165 Pollock, 2002, Stereotactic radiosurgery for patients with ACTH-producing pituitary adenomas after prior adrenalectomy, Int. J. Radiat. Oncol. Biol. Phys., 54, 639, 10.1016/S0360-3016(02)02975-9 Assie, 2007, Corticotroph tumor progession after adrenalectomy in Cushing’s disease: a reappraisal of Nelson’s syndrome, J. Clin. Endocrinol. Metab., 92, 172, 10.1210/jc.2006-1328 Kelly, 2002, Neurosurgical treatment of Nelson’s Syndrome, J. Clin. Endocrinol. Metab., 87, 5465, 10.1210/jc.2002-020299 Jane, 2003, Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach, Neurosurg. Focus, 14, e12, 10.3171/foc.2003.14.5.13 Kelly, 1988, Long-term treatment of Nelson's syndrome with sodium valproate, Clin. Endocrinol. (Oxf.), 28, 195, 10.1111/j.1365-2265.1988.tb03656.x Mercado-Assis, 1997, Acute effects of bromocriptine, cyproheptadine, and valproic acid on plasma adrenocorticotropin secretion in Nelson’s syndrome, J. Clin. Endocrinol. Metab., 82, 514, 10.1210/jc.82.2.514 Kasperlik-Zaluska, 2005, ACTH response to somatostatin, valproic acid and dexamethasone in Nelson’s syndrome, Neuroendocrinol. Lett., 26, 709 Petrini, 1994, Long-term treatment of Nelson’s syndrome by octreotide: a case report, J. Endocrinol. Invest., 17, 135, 10.1007/BF03347703 De Herder, 1996, Somatostatin analogue treatment of neuroendocrine tumours, Postgrad. Med. J., 72, 403, 10.1136/pgmj.72.849.403 Bruns, 2002, SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile, Eur. J. Endocrinol., 146, 707, 10.1530/eje.0.1460707 Hofland, 2005, The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptors type 5, Eur. J. Endocrinol., 152, 645, 10.1530/eje.1.01876 Batista, 2006, The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas, J Clin Endocrinol Metab, 91, 4482, 10.1210/jc.2006-1245 Andreassen, 2005, Rosiglitazone for prevention or adjuvant treatment of Nelson’s syndrome after bilateral adrenalectomy, Eur. J. Endocrinol., 153, 503, 10.1530/eje.1.01994 Mullan, 2006, The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson’s syndrome, Clin. Endoc., 64, 519, 10.1111/j.1365-2265.2006.02501.x Pivonello, 1999, Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline, J. Endocrinol. Invest., 22, 860, 10.1007/BF03343660 Casulari, 2004, Nelson’s syndrome: complete remission with cabergoline, but not with bromocriptine or cyproheptadine treatment, Horm. Res., 62, 300, 10.1159/000082235 Shraga-Slutzky, 2006, Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment, Pituitary, 9, 151, 10.1007/s11102-006-9290-4